Prognostic Significance of the Combined Expression of Matrix Metalloproteinase-9, Urokinase Type Plasminogen Activator and its Receptor in Breast Cancer as Measured by Northern Blot Analysis

Pacheco, Mariana Poltronieri; Nishimoto, Inês Nobuko; Neto, Mário Mourão; Mantovani, E.; Brentani, Maria Mitzi

doi:10.1177/172460080101600109

Cited by 26 publications

(19 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, NF-B may regulate the production of prostaglandins via the proinflammatory gene cyclooxygenase-2 (COX2), which has been shown to be overexpressed in a variety of cancers including colorectal cancer and mesothelioma. [109][110][111] Similar studies have been found for many other pro-inflammatory genes regulated by NF-B including tumor necrosis factor 112 (TNF), interleukin-1 113 (IL-1), inducible NO-synthase 114 (iNOS), matrix metalloproteinase 115 (MMP-9), urokinase-type plasminogen activator 116 (uPA), and many other chemokines. [117][118][119] …”

Section: Nf-b and Tumor Promotionmentioning

confidence: 70%

Nuclear transcription factor-κB as a target for cancer drug development

2002

View full text Add to dashboard Cite

Nuclear factor kappa B (NF-B) is a family of inducible transcription factors found virtually ubiquitously in all cells. Since its discovery by Sen and Baltimore in 1986, much has been discovered about its mechanisms of activation, its target genes, and its function in a variety of human diseases including those related to inflammation, asthma, atherosclerosis, AIDS, septic shock, arthritis, and cancer. Due to its role in a wide variety of diseases, NF-B has become one of the major targets for drug development. Here, we review our current knowledge of NF-B, the possible mechanisms of its activation, its potential role in cancer, and various strategies being employed to target the NF-B signaling pathway for cancer drug development.

show abstract

Section: Nf-b and Tumor Promotionmentioning

confidence: 70%

Nuclear transcription factor-κB as a target for cancer drug development

2002

View full text Add to dashboard Cite

show abstract

“…UPAR activation ultimately leads to the degradation of the extracellular matrix, which seems to be necessary for functions as diverse as the local invasion and metastasis of tumor cells and for nerve growth factor-induced PC12 cell neurite outgrowth (19)(20)(21). Pacheco et al (22), using Northern blot analysis, measured the coexpression of the matrix metalloprotease MMP-9, UPA, and UPAR mRNAs in biopsy samples from patients with breast cancer and found that increased UPAR mRNA levels were associated with poor prognosis. In addition, it has been reported that sUPAR is a useful prognostic marker for patients with ovarian, breast, prostate, and colon cancer (23)(24)(25)(26)(27), although sUPAR has no known physiological function.…”

Section: Discussionmentioning

confidence: 99%

Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer

Memarzadeh

Kozak

Chang

et al. 2002

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Endometrial adenocarcinoma is the most common gynecologic malignancy in the United States. However, reliable diagnostic or prognostic tumor markers have not been identified for endometrial cancer. In this study, we examined whether urokinase plasminogen activator receptor (UPAR), a glycosyl-phosphatidylinositol-linked membrane protein, is a candidate diagnostic or prognostic marker for patients with cancer of the endometrium. Sixty-five surgically excised, formalin-fixed endometrial tissue specimens were accessioned through the Department of Pathology Registry at the University of California, Los Angeles, and analyzed for UPAR expression by using immunohistochemical techniques. A retrospective review was also performed to determine stage and histopathologic grade of disease, recurrence, and mortality. No expression of UPAR protein was present in seven patients with benign neoplasia of the endometrium. UPAR protein expression highly correlated with stage of disease (ungrouped Spearman correlation = 0.625, P < 0.0001): 40% of patients with stage I, 66% of patients with stage II, 100% of patients with stage III, and 85% with stage IV demonstrated the highest level of UPAR expression. Moreover, high UPAR expression positively correlated with grade of disease (ungrouped Spearman correlation = 0.71, P < 0.0001): 29% of grade 1 specimens, 57% of grade 2, and over 90% of specimens with grade 3, the majority representing uterine papillary serous carcinoma and mixed malignant mesodermal tumor. Finally, UPAR protein expression also positively correlated with rate of recurrence and mortality in patients with adenocarcinoma of the endometrium (ungrouped P = 0.034). Our data suggest that UPAR is a useful prognostic marker for biologically aggressive forms of endometrial cancer

show abstract

“…Ets-2 is involved in protein kinase A-stimulated hCG␤-5 expression (25 ) and is also involved in urokinase-type plasminogen activator and matrix metalloprotease-9 gene expression (26 ). Urokinase-type plasminogen activator and matrix metalloprotease-9 are matrix-degrading enzymes with prognostic value in breast cancer (27,28 ).…”

Section: Discussionmentioning

confidence: 99%

Molecular Beacon Reverse Transcription-PCR of Human Chorionic Gonadotropin-β-3, -5, and -8 mRNAs Has Prognostic Value in Breast Cancer

Span¹,

Manders²,

Heuvel³

et al. 2003

Clinical Chemistry

View full text Add to dashboard Cite

Background:The ␤-subunit of human chorionic gonadotropin (hCG) is encoded by four genes, of which expression of the hCG␤-3, -5, and -8 genes could have prognostic value in breast cancer. Methods: Applying a new, modified Molecular Beacon reverse transcription-PCR assay, we investigated the prognostic value of the hCG␤-3, -5, and -8 gene transcripts in 129 sporadic unilateral breast cancer samples from patients with a median follow-up of 62.3 months. Results: Expression of hCG␤-3, -5, -8 was significantly (P ‫؍‬ 0.020) associated with relapse-free survival (RFS). In multivariate survival analysis, hCG␤-3, -5, and -8 maintained prognostic value for RFS, with high expression predicting shorter RFS (P ‫؍‬ 0.015; hazard ratio, 2.25; 95% confidence interval, 1.17-4.34). Only 1 of 24 (4%) node-negative patients with low hCG␤-3, -5, -8 expression relapsed, in contrast to 7 of 26 (27%) patients with high expression (P ‫؍‬ 0.046). Conclusions: Expression of hCG␤-3, -5, -8, which differ by only one nucleotide from other hCG␤ genes, can be assessed by our modified Molecular Beacon assay in breast cancer tissues. Expression of hCG␤-3, -5, -8 has independent, prognostic value for RFS in breast cancer and may help identify node-negative patients with poor prognosis.

show abstract

Prognostic Significance of the Combined Expression of Matrix Metalloproteinase-9, Urokinase Type Plasminogen Activator and its Receptor in Breast Cancer as Measured by Northern Blot Analysis

Cited by 26 publications

References 28 publications

Nuclear transcription factor-κB as a target for cancer drug development

Nuclear transcription factor-κB as a target for cancer drug development

Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer

Molecular Beacon Reverse Transcription-PCR of Human Chorionic Gonadotropin-β-3, -5, and -8 mRNAs Has Prognostic Value in Breast Cancer

Contact Info

Product

Resources

About